Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8134144 | 0.87 | GABRA1 (0.42) | GABRA1LMNAGABRB2GABRG2GABRB3 | |
| SCHEMBL11314594 | 0.87 | CA1 (0.43) | GABRA1LMNAGABRB2GABRG2GABRB3 | |
| SCHEMBL28980492 | 0.87 | GABRA1 (0.41) | GABRA1LMNAGABRB2GABRG2GABRB3 | |
| SCHEMBL11555903 | 0.85 | CYP1A2 (0.42) | GABRA1LMNAGABRB2GABRG2GABRB3 | |
| SCHEMBL1868729 | 0.85 | GABRA1 (0.59) | GABRA1LMNAGABRB2GABRG2GABRB3 | |
| SCHEMBL30791332 | 0.82 | KCNK3 (0.47) | CA1CA2CYP1A2CYP3A4HPGD | |
| SCHEMBL2048068 | 0.81 | GABRA1 (0.60) | GABRA1LMNAGABRB2GABRG2GABRB3 | |
| SCHEMBL23058348 | 0.79 | GABRA1 (0.43) | GABRA1LMNAGABRB2GABRG2GABRB3 | |
| SCHEMBL5670849 | 0.79 | CYP3A4 (0.43) | GABRA1LMNAGABRB2GABRG2GABRB3 | |
| SCHEMBL1073583 | 0.79 | GABRA1 (0.54) | GABRA1LMNAGABRB2GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119684099-A | Preparation method of 3- (3-isopropylphenyl) butyraldehyde | 西安凯立新材料股份有限公司 | 2025-03-25 | — | — | CN | claimed |
| US-11787827-B2 | Triaryl phosphine ligands, preparation method therefor, and use in catalyzing coupling reactions | DONGGUAN STEPHEN CATALYST CO., LTD. (CN) | 2023-10-17 | — | — | US | claimed |
| CN-115385956-A | Biaryl diphosphine ligands and transition metal complexes thereof | 东莞市均成高新材料有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-115385957-A | Linear terphenyl aryl phosphine ligand and transition metal complex thereof | 东莞市均成高新材料有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-115385955-A | Tetrabiarylphosphine ligands and transition metal complexes thereof | 东莞市均成高新材料有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-115181128-A | Phosphine ligand of arylmethyl biaryl and transition metal complex thereof | 东莞市均成高新材料有限公司 | 2022-10-14 | — | — | CN | claimed |
| US-20210147452-A1 | TRIARYL PHOSPHINE LIGANDS, PREPARATION METHOD THEREFOR, AND USE IN CATALYSING COUPLING REACTIONS | DONGGUAN STEPHEN CATALYST CO., LTD. (CN) | 2021-05-20 | — | — | US | claimed |
| EP-3766891-A1 | TRIARYL PHOSPHINE LIGANDS, PREPARATION METHOD THEREFOR, AND USE IN CATALYSING COUPLING REACTIONS | Dongguan Stephen Catalyst Co., Ltd. (CN) | 2021-01-20 | — | — | EP | claimed |
| WO-2019170163-A1 | TRIARYL PHOSPHINE LIGANDS, PREPARATION METHOD THEREFOR, AND USE IN CATALYSING COUPLING REACTIONS | 东莞市均成高新材料有限公司 | 2019-09-12 | — | — | WO | claimed |
| US-8766529-B2 | Metal complexes of cyclometallated imidazo[1,2-ƒ]phenanthridine and diimidazo[1,2-a:1',2'-c]quinazoline ligands and isoelectronic and benzannulated analogs thereof | UNIVERSAL DISPLAY CORPORATION (US) | 2014-07-01 | — | — | US | claimed |
| EP-4703362-A1 | COMPOUND CONTAINING OXO-PYRIDO-ALIPHATIC RING OR ALIPHATIC HETEROCYCLIC STRUCTURE, AND MEDICAL USE THEREOF | Chengdu Sibeibo Pharmaceutical Technology Co., Ltd (CN) | 2026-03-04 | — | — | EP | disclosed |
| WO-2025061141-A1 | PHARMACEUTICAL COMPOSITION HAVING IMPROVED PHARMACOKINETIC PROPERTIES | 成都思倍博医药科技有限公司 | 2025-03-27 | — | — | WO | disclosed |
| CN-119684099-A | Preparation method of 3- (3-isopropylphenyl) butyraldehyde | 西安凯立新材料股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| US-12258323-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2025-03-25 | — | — | US | disclosed |
| CN-119604497-A | Heteroaromatic carboxamides and their use in medicine | 远森制药（杭州）有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-115181128-A | Phosphine ligand of arylmethyl biaryl and transition metal complex thereof | 东莞市均成高新材料有限公司 | 2022-10-14 | — | — | CN | disclosed |
| US-11427553-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-30 | — | — | US | disclosed |
| EP-3661917-B1 | 6-((3-TRIFLUOROMETHYL)PHENYL)-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | BAYER AG (DE) | 2022-05-11 | — | — | EP | disclosed |
| US-20210147452-A1 | TRIARYL PHOSPHINE LIGANDS, PREPARATION METHOD THEREFOR, AND USE IN CATALYSING COUPLING REACTIONS | DONGGUAN STEPHEN CATALYST CO., LTD. (CN) | 2021-05-20 | — | — | US | disclosed |
| EP-3766891-A1 | TRIARYL PHOSPHINE LIGANDS, PREPARATION METHOD THEREFOR, AND USE IN CATALYSING COUPLING REACTIONS | Dongguan Stephen Catalyst Co., Ltd. (CN) | 2021-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787827-B2 | Triaryl phosphine ligands, preparation method therefor, and use in catalyzing coupling reactions | WEE1, WEE2, NOTUM | GABRA1 958/4885LMNA 4765/4885GABRB2 1914/4885 |
| US-12258323-B2 | Dihydrooxadiazinones | CCND2, CCNT2, CCND1 | GABRA1 4514/4885LMNA 832/4885GABRB2 4666/4885 |
| US-20210147452-A1 | TRIARYL PHOSPHINE LIGANDS, PREPARATION METHOD THEREFOR, AND USE IN CATALYSING COUPLING REACTIONS | WEE1, WEE2, NOTUM | GABRA1 751/4885LMNA 4759/4885GABRB2 1745/4885 |
| US-11427553-B2 | Dihydrooxadiazinones | CCND2, CCNT2, CCND1 | GABRA1 4514/4885LMNA 832/4885GABRB2 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.